Autres langues Athira Pharma, Inc.

Actions

ATHA

US04746L1044

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/05/2024			Varia. 5j.	Varia. 1 janv.
1,96 ^USD	-3,92%		+2,08%	-19,34%

15/04	Athira Pharma, Inc. nomme Javier San Martin, M.D., au poste de Chief Medical Officer	CI
11/04	Athira Pharma, Inc. annonce la publication de données précliniques mettant en évidence le traitement par fosgoniméton dans des modèles de la maladie d'Alzheimer	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Athira Pharma to Participate in Upcoming May Conferences	02/05
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer	15/04
Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer	15/04
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's disease	12/04
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease	11/04
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease	11/04
Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease	11/04
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting	03/04
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference	08/03
Athira Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates	22/02
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)	08/02
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)	08/02
Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis	08/02
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update	08/01
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update	08/01
Athira Pharma, Inc. Provides 2024 Clinical Pipeline Outlook	08/01
Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer	08/01
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease	03/01
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease	03/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Athira Pharma, Inc.

Actions

ATHA

US04746L1044

Autres langues

Filtres